Incidence of Relapse 2 Years [clinicaltrials_resource:3aff3cc0ea83732216d9478b0330ccfe]
To measure the impact of donor selection for KIR genotype in allogeneic URD HCT for AML on cumulative incidence of relapse. We will determine a quantitative estimate of the likelihood of better KIR donors identified with routine, non-directed donor selection along with KIR genotyping data. The observed incidence of success in a better KIR donor identified within 8 weeks will be compared to the original donor genotype expected frequencies identified in our retrospective genotyping of 1086 donors selected for AML transplants.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Incidence of Relapse 2 Years [clinicaltrials_resource:3aff3cc0ea83732216d9478b0330ccfe]
To measure the impact of donor selection for KIR genotype in allogeneic URD HCT for AML on cumulative incidence of relapse. We will determine a quantitative estimate of the likelihood of better KIR donors identified with routine, non-directed donor selection along with KIR genotyping data. The observed incidence of success in a better KIR donor identified within 8 weeks will be compared to the original donor genotype expected frequencies identified in our retrospective genotyping of 1086 donors selected for AML transplants.
Bio2RDF identifier
3aff3cc0ea83732216d9478b0330ccfe
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3aff3cc0ea83732216d9478b0330ccfe
measure [clinicaltrials_vocabulary:measure]
Incidence of Relapse
time frame [clinicaltrials_vocabulary:time-frame]
description
To measure the impact of donor ...... selected for AML transplants.
identifier
clinicaltrials_resource:3aff3cc0ea83732216d9478b0330ccfe
title
Incidence of Relapse 2 Years
@en
type
label
Incidence of Relapse 2 Years [clinicaltrials_resource:3aff3cc0ea83732216d9478b0330ccfe]
@en